The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CD133 status influences in prognosis of patients with metastatic colorectal cancer receiving cetuximab.
Dai Inoue
No relevant relationships to disclose
Satoshi Matsusaka
No relevant relationships to disclose
Noriko Yamamoto
No relevant relationships to disclose
Mitsukuni Suenaga
No relevant relationships to disclose
Yuji Mishima
No relevant relationships to disclose
Eiji Shinozaki
No relevant relationships to disclose
Yasuhito Terui
No relevant relationships to disclose
Nobuyuki Mizunuma
No relevant relationships to disclose
Yuichi Ishikawa
No relevant relationships to disclose
Kiyohiko Hatake
No relevant relationships to disclose